Matthew H Lucas

US Patent:

8093285, Jan 10, 2012

Filed:

Mar 25, 2009

Appl. No.:

12/383538

Inventors:

Pravin Iyer - Palo Alto CA, US
Matthew C. Lucas - Sunnyvale CA, US
Ryan Craig Schoenfeld - San Jose CA, US
Robert James Weikert - Boulder Creek CA, US

Assignee:

Roche Palo Alto LLC - Palo Alto CA

International Classification:

A01N 43/38

US Classification:

514414, 514415, 514329, 548469, 546184

Abstract:

This application discloses aminopiperidinyl compounds of generic Formulae I-II:.

US Patent:

8158625, Apr 17, 2012

Filed:

May 26, 2010

Appl. No.:

12/787608

Inventors:

Georgette Castanedo - Redwood City CA, US
David Goldstein - Nutley NJ, US
Rama Kondru - Nutley NJ, US
Matthew Lucas - Nutley NJ, US
Wylie Palmer - Nutley NJ, US
Stephen Price - Harlow, GB
Brian Safina - Redwood City CA, US
Pascal Pierre Alexandre Savy - Harlow, GB
Eileen Mary Seward - Harlow, GB
Daniel P. Sutherlin - Burlingame CA, US
Zachary K. Sweeney - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/535
C07D 413/14

US Classification:

5142342, 544117

Abstract:

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, (iv) Xis CRand Xis O, or (v) Xis CRand Xis NR, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

8173650, May 8, 2012

Filed:

May 26, 2010

Appl. No.:

12/787613

Inventors:

Georgette Castanedo - Redwood City CA, US
Bryan Chan - San Carlos CA, US
David Goldstein - Nutley NJ, US
Rama Kondru - Nutley NJ, US
Matthew Lucas - Nutley NJ, US
Wylie Palmer - Nutley NJ, US
Stephen Price - Harlow, GB
Brian Safina - Redwood City CA, US
Pascal Pierre Alexandre Savy - Harlow, GB
Eileen Mary Seward - Harlow, GB
Daniel P. Sutherlin - Burlingame CA, US
Zachary K. Sweeney - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/535
C07D 413/14

US Classification:

5142342, 544118

Abstract:

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

8394796, Mar 12, 2013

Filed:

Mar 22, 2012

Appl. No.:

13/427081

Inventors:

Georgette Castanedo - Redwood City CA, US
Bryan Chan - San Carlos CA, US
David Goldstein - Nutley NJ, US
Rama Kondru - Nutley NJ, US
Matthew Lucas - Nutley NJ, US
Wylie Palmer - Nutley NJ, US
Stephen Price - Harlow, GB
Brian Safina - Redwood City CA, US
Pascal Pierre Alexandre Savy - Harlow, GB
Eileen Mary Seward - Harlow, GB
Daniel P. Sutherlin - Burlingame CA, US
Zachary K. Sweeney - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/535

US Classification:

5142342

Abstract:

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

8440651, May 14, 2013

Filed:

Feb 18, 2011

Appl. No.:

13/030246

Inventors:

Georgette Castanedo - Redwood City CA, US
Bryan Chan - San Carlos CA, US
Matthew C. Lucas - Nutley NJ, US
Brian Safina - Redwood City CA, US
Daniel P. Sutherlin - Burlingame CA, US
Zachary Sweeney - Redwood City CA, US

Assignee:

F. Hoffmann-La Roche AG - Basel

International Classification:

A61K 31/397
A61K 31/5377
C07D 413/14

US Classification:

51421021, 5142342, 5142325, 544117, 544 82

Abstract:

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

8563540, Oct 22, 2013

Filed:

Apr 1, 2013

Appl. No.:

13/854635

Inventors:

Bryan Chan - San Carlos CA, US
Matthew C. Lucas - Nutley NJ, US
Brian Safina - Redwood City CA, US
Daniel P. Sutherlin - Burlingame CA, US
Zachary Sweeney - Redwood City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/397
A61K 31/5377
C07D 413/14

US Classification:

51421021, 5142342, 5142325, 544117, 544 82

Abstract:

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

US Patent:

20130109661, May 2, 2013

Filed:

Oct 31, 2012

Appl. No.:

13/665006

Inventors:

Andreas Kuglstatter - Loerrach, DE
Matthew C. Lucas - Lexington MA, US
Fernando Padilla - Verona NJ, US
Jutta Wanner - Montclair NJ, US
Xiaohu Zhang - Suzhou, CN

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07D 487/04
A61K 45/06
A61K 31/625
A61K 31/5025
A61K 31/5377

US Classification:

514161, 544236, 514248, 544117, 5142332

Abstract:

The present invention relates to the use of novel compounds of formula I:wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

US Patent:

20220298168, Sep 22, 2022

Filed:

Sep 22, 2020

Appl. No.:

17/028778

Inventors:

- Cambridge MA, US
Matthew LUCAS - Lexington MA, US
Kerem OZBOYA - Cambridge MA, US
Bhaumik PANDYA - Bedford MA, US
Daniel TARDIFF - Arlington MA, US
Parcharee TIVITMAHAISOON - Boston MA, US
Iwona WRONA - Sharon MA, US

International Classification:

C07D 491/107
C07D 237/04
C07D 401/12
C07D 237/24
C07D 213/82
C07D 403/12
C07D 409/14
C07D 487/04
C07D 401/14
C07D 471/04
C07D 405/14
C07D 413/12
C07D 417/12
C07D 513/04
C07D 417/14
C07D 495/04

Abstract:

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.